Aims Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular
death among patients with heart failure with mildly reduced or preserved ejection fraction. In …

Introduction Despite the progress made in the treatment of heart failure with reduced
ejection fraction (HFrEF) in recent years, the prognosis of the disease remains poor, with …

OBJECTIVE The sodium–glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of
cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of …

Importance Sodium glucose cotransporter 2 inhibitors reduce morbidity and mortality in
patients with heart failure and reduced ejection fraction (HFrEF). Clinicians may find …

Background Patients with heart failure with reduced ejection fraction (HFrEF) in Asia exhibit
many differences from those in other parts of the world. Objectives This study sought to …

Objectives This study assessed the efficacy and safety of dapagliflozin in patients who were
or were not taking sacubitril/valsartan at baseline in the DAPA-HF (Study to Evaluate the …

Background: Heart failure (HF) is a major cause of recurrent hospitalization and death
worldwide. Sodium-glucose cotransporter-2 inhibitors including dapagliflozin are anti …

Aims Patients recently hospitalized for heart failure (HF) often have unstable
haemodynamics and experience worsening renal failure, and are at elevated risk for …

The sodium-glucose cotransporter-2 inhibitor dapagliflozin was recently demonstrated to
reduce the combined risk of cardiovascular death or worsening heart failure (HF) in the …

Abstract Aims The Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved
Ejection Fraction Heart Failure (DELIVER) trial demonstrated the sodium–glucose …